# Vertex Acquires Crinetics Pharmaceuticals for $10 Billion in Largest Deal in Vertex History

> ma · REPORTED · 2026-07-06

Vertex Pharmaceuticals announced on July 6, 2026 a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, totaling approximately $10 billion, to gain the approved acromegaly drug Palsonify (paltusotine) and late-stage pipeline candidate atumelnant for congenital adrenal hyperplasia. The deal, unanimously approved by both boards, is expected to close in Q3 2026 and is the fourth-largest biotech M&A by proceeds this year.

About Vertex Pharmaceuticals / Crinetics Pharmaceuticals: Crinetics Pharmaceuticals is a commercial-stage global pharmaceutical company focused on the discovery, development, and commercialization of novel small-molecule therapeutics for rare endocrine diseases including acromegaly and congenital adrenal hyperplasia.

- Company: Vertex Pharmaceuticals / Crinetics Pharmaceuticals
- Sector: therapeutics
- Primary source: https://www.biopharmadive.com/news/vertex-crinetics-acquire-deal-palsonify-acromegaly/824545/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.